Journal of Medical and Clinical Nursing Studies

Advancements in Gynecology: A Comprehensive Review of Emerging Research and Innovations

Kirolos Eskandar

Helwan University, Faculty of Medicine and Surgery, Egypt

Corresponding author
Kirolos Eskandar, Helwan University, Faculty of Medicine and Surgery, Egypt.

ABSTRACT
With recent groundbreaking advancements in gynecology, women’s reproductive health care has entered a transformative era. This literature review explores ten key subtopics, unveiling cutting-edge developments that are reshaping the field. Did you know that minimally invasive gynecological procedures have revolutionized patient recovery and treatment outcomes? Or that precision medicine is now leveraging genetic profiling for personalized gynecological treatments? From revolutionary ART techniques to innovative gynecological oncology therapies, this review provides concise insights into the latest breakthroughs. Additionally, it examines advancements in contraceptive methods, digital health integration, and the impact of psychological factors on gynecological health. Emphasizing patient perspectives and shared decision-making, this review paints an exciting picture of a patient-centric future for gynecological practice.

Keywords: Minimally Invasive Procedures, Precision Medicine, Assisted Reproductive Technologies, Gynecological Oncology, Patient-Centric Care

Introduction
Women’s health care has witnessed remarkable advancements in gynecology over the past few decades, driven by cutting-edge research, technological innovations, and a growing emphasis on patient-centric care. This comprehensive literature review aims to provide a detailed overview of ten key subtopics that exemplify recent developments in the field, offering insights into the progress made and potential future directions.

Gynecological surgery has undergone a paradigm shift with the introduction of minimally invasive procedures, such as laparoscopy and robotic-assisted surgery. These techniques have gained popularity due to their numerous benefits, including reduced postoperative pain, shorter hospital stays, faster recovery times, and improved patient satisfaction [1,2]. Precision medicine has emerged as a transformative approach in gynecology, tailoring treatment strategies based on individual characteristics, such as genetic and molecular profiling. Personalized therapies offer the potential for enhanced treatment efficacy and minimized adverse effects [3,4].

Advances in assisted reproductive technologies (ART) have revolutionized fertility treatments, providing hope to millions of couples struggling with infertility worldwide. Techniques like in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT) have significantly improved pregnancy rates and minimized the risk of genetic disorders [5,6]. Gynecological oncology has experienced significant progress, driven by ongoing research into novel treatment modalities. Targeted therapies, immunotherapy, and the application of liquid biopsies have transformed the landscape of gynecologic cancer management, leading to improved survival rates and enhanced quality of life for affected patients [7,8].

Recent research has expanded contraceptive options for women, including the development of long-acting reversible contraceptives (LARCs) and non-hormonal methods. These advancements aim to provide safer and more effective choices for family planning [9,10]. Furthermore, the integration of digital health tools, telemedicine platforms, and mobile applications has the potential to revolutionize gynecological care. Improved patient access, remote monitoring, and enhanced healthcare delivery have become possible through these technological advancements [11,12].

The management of menopause has also evolved with the introduction of an array of hormonal therapies. Bioidentical hormones, selective estrogen receptor modulators (SERMs), and other novel agents have been extensively researched to alleviate menopausal symptoms and maintain long-term health [13, 14]. Additionally, the emergence of infectious diseases poses new challenges to gynecological health. Research has explored the associations between certain viruses and gynecological conditions, emphasizing the need for vigilance and ongoing investigation [15,16].

Taking a holistic approach to gynecological care, understanding the significance of mental health is crucial. Recognizing the interplay between psychological factors and gynecological conditions is vital to provide comprehensive and patient-centric care [17,18]. Finally, the importance of patient perspectives and preferences is increasingly acknowledged in gynecological practice. Shared decision-making has gained traction, empowering patients to actively participate in treatment choices and fostering better adherence and overall satisfaction with healthcare outcomes [19,20].

By exploring these subtopics, this literature review aims to provide a comprehensive and informative account of the recent advancements in gynecology. The insights gained from this analysis are expected to contribute to ongoing research efforts, clinical practice, and policy-making, ultimately improving the overall quality of women’s health care.

Minimally Invasive Gynecological Procedures
Minimally invasive gynecological procedures have revolutionized the field of gynecology, offering significant benefits over traditional open surgeries. Two prominent techniques that have gained widespread adoption are laparoscopy and robotic-assisted procedures. Laparoscopy, also known as minimally invasive surgery or keyhole surgery, involves the insertion of a thin, lighted tube (laparoscope) through small incisions in the abdominal wall to visualize and access the pelvic organs [1]. Compared to open surgeries, laparoscopic procedures have demonstrated several advantages, including reduced postoperative pain, shorter hospital stays, faster recovery times, and improved cosmetic outcomes with minimal scarring [21]. These benefits translate to enhanced patient satisfaction and reduced healthcare costs [22].

Robotic-assisted procedures further refine the capabilities of minimally invasive surgery. The enhanced precision and three-dimensional visualization provided by robotic systems enable complex surgeries with improved outcomes [23]. Robotic platforms allow for a greater range of motion, fine manipulation of tissues, and reduction of surgeon fatigue, all contributing to better patient outcomes [24]. As a result, robotic-assisted surgeries have gained popularity in the field of gynecology, especially for procedures like hysterectomy and myomectomy [2]. Studies comparing robotic-assisted laparoscopic surgery to conventional laparoscopy have shown comparable outcomes, with robotic surgery demonstrating advantages in certain aspects, such as lower blood loss and shorter hospital stays [25].

In gynecology, minimally invasive procedures have revolutionized the management of various conditions, including benign gynecological disorders, endometriosis, and gynecologic cancers [26]. For instance, minimally invasive approaches have become the preferred choice for hysterectomy, myomectomy, and ovarian cystectomy due to their safety and efficacy [27]. Studies have demonstrated that laparoscopic hysterectomy has lower complication rates and quicker return to normal activities compared to abdominal hysterectomy [28]. Furthermore, minimally invasive surgery has been associated with reduced intraoperative blood loss and decreased postoperative analgesic requirements [29].

Moreover, the implementation of minimally invasive techniques has facilitated the adoption of fertility-preserving surgeries, particularly in cases of early-stage gynecological cancers [30]. By preserving the patient’s fertility, these surgical advancements provide an added dimension of care and address the reproductive concerns of young women diagnosed with gynecological malignancies. Several studies have shown that minimally invasive surgery, including laparoscopic radical trachelectomy, can effectively preserve fertility while maintaining oncological safety [31,32]. Additionally, robotic-assisted laparoscopic surgery for early-stage cervical cancer has been associated with favorable survival outcomes and reduced morbidity [33].

Despite these remarkable advancements, there are certain challenges associated with minimally invasive gynecological procedures. These include the learning curve for surgeons, cost considerations related to robotic platforms, and specific patient factors that may affect the feasibility of minimally invasive surgery [34]. However, research has shown that once surgeons surpass the initial learning curve, the benefits of minimally invasive procedures become more apparent in terms of patient outcomes and recovery [35]. Proper training and continued education for surgeons in minimally invasive techniques are essential to ensure successful adoption and safe implementation of these procedures.

Precision Medicine in Gynecology
Bioprocessing Precision medicine, an emerging paradigm in gynecology, represents a transformative shift in healthcare that aims to provide personalized and tailored treatment strategies for individual patients. This approach leverages advancements in genetics, molecular biology, and biomarker analysis to understand the unique characteristics of each patient’s disease, enabling clinicians to deliver targeted interventions with improved therapeutic outcomes and minimized adverse effects.

Genetic profiling forms the cornerstone of precision medicine in gynecology, offering valuable insights into an individual’s inherited genetic predisposition to gynecological disorders and potential responsiveness to specific treatments. In cases of hereditary gynecologic cancers, such as hereditary breast and ovarian cancer (HBOC) syndrome, genetic testing for BRCA1 and BRCA2 mutations has become an essential component of clinical practice [36]. Identification of these mutations allows for targeted surveillance, risk-reducing surgeries, and the use of novel therapies, such as PARP inhibitors, which have shown promising results in BRCA-mutated ovarian cancers [37].

Molecular profiling is another crucial aspect of precision medicine in gynecology, as it unveils the unique molecular characteristics and signaling pathways of gynecological tumors. Substantial progress in molecular techniques has led to the identification of distinct subtypes of gynecological cancers, such as endometrial cancer, each with varying clinical behaviors and prognoses [38]. This molecular classification has paved the way for the development of targeted therapies tailored to specific subtypes, including hormonal therapies for hormone receptor-positive endometrial cancers and immune checkpoint inhibitors for mismatch repair-deficient endometrial cancers [39,40].

Biomarker profiling serves as a complementary tool to genetic and molecular profiling, providing valuable information about specific biomolecules that indicate disease presence, prognosis, or response to treatment. In ovarian cancer management, serum CA-125 levels have long been utilized for monitoring treatment response and detecting disease recurrence [41]. Emerging biomarkers such as HE4 and ROMA (Risk of Ovarian Malignancy Algorithm) have shown potential as adjuncts to CA-125 in improving ovarian cancer detection and risk assessment [42].

The integration of precision medicine in gynecological practice extends beyond oncology and encompasses reproductive health. Genetic screening and counseling have become pivotal in identifying hereditary conditions in couples, guiding family planning decisions, and reducing the risk of passing on inherited disorders to offspring. Preimplantation genetic testing (PGT) offers the opportunity to select embryos free from genetic defects before IVF embryo transfer, significantly lowering the risk of transmitting hereditary conditions to future generations [43]. Moreover, personalized approaches based on individual hormonal profiles have shown promise in optimizing fertility treatment outcomes, leading to better success rates in assisted reproductive technologies [44].

Despite its tremendous potential, the implementation of precision medicine in gynecology faces several challenges. Access to genetic testing and molecular analysis, cost considerations, and ethical implications related to genetic information are critical factors that require thoughtful consideration. Additionally, incorporating genomic data into routine clinical practice necessitates the training of healthcare professionals and the establishment of robust bioinformatics infrastructure [45].

Advances in Reproductive Medicine
Reproductive medicine has experienced remarkable advancements, particularly in the field of assisted reproductive technologies (ART), which offer hope and solutions to couples facing infertility challenges. Among these breakthroughs, in vitro fertilization (IVF) stands as the most transformative technique, revolutionizing the treatment of various causes of infertility and enabling millions of couples to realize their dream of parenthood [46].

In vitro fertilization (IVF) involves the fertilization of eggs and sperm outside the woman’s body in a controlled laboratory setting. Over the years, improvements in IVF protocols, culture media, and laboratory techniques have significantly enhanced success rates [47]. The introduction of techniques such as intracytoplasmic sperm injection (ICSI) has revolutionized male infertility treatment by allowing for the direct injection of a single sperm into the egg, overcoming severe male factor infertility [48]. Additionally, advancements in embryo culture conditions have led to the development of time-lapse imaging systems, which enable continuous monitoring of embryo development, aiding in the selection of the most viable embryos for transfer [49].

Embryo selection techniques have become pivotal in maximizing the chances of a successful pregnancy during IVF. Preimplantation genetic testing (PGT) is a groundbreaking approach that allows for the genetic analysis of embryos before transfer. PGT enables the identification of chromosomally normal embryos, minimizing the risk of implantation failure and miscarriage [50]. Moreover, PGT has proven beneficial in detecting single gene disorders, such as cystic fibrosis and thalassemia, thereby preventing the transmission of genetic conditions to offspring [51].

The evolving field of fertility preservation has been instrumental in addressing the reproductive needs of individuals facing challenges to their future fertility. For women diagnosed with cancer or other medical conditions that may compromise their fertility, fertility preservation techniques offer the opportunity to safeguard their ability to conceive in the future. Oocyte cryopreservation, also known as egg freezing, has emerged as a viable option for preserving female fertility, allowing women to preserve their eggs when young and healthy, for later use when ready to start a family [52]. Moreover, advances in ovarian tissue cryopreservation have shown promise as an experimental technique to preserve the fertility of prepubertal girls and women who cannot undergo conventional fertility preservation methods [53].

Furthermore, fertility preservation has expanded to include options for males. Sperm cryopreservation offers a simple and effective way for men to preserve their fertility before undergoing medical treatments that may impact sperm production or quality [54]. Additionally, advancements in testicular tissue cryopreservation present a potential avenue for preserving fertility in prepubertal boys who are not yet producing mature sperm [55]. Despite these significant advancements, challenges persist in the field of reproductive medicine. One major concern is the cost of ART, which can be prohibitive for many couples. Moreover, while IVF success rates have improved, there are still variations in outcomes based on factors such as age, underlying infertility causes, and the number of embryos transferred. Addressing these challenges requires ongoing research and innovations in ART techniques, as well as increased accessibility and affordability for patients.

Innovations in Gynecological Oncology
In recent years, the field of gynecological oncology has experienced remarkable advancements, leading to improved outcomes and new treatment opportunities for women diagnosed with gynecological cancers. These innovations have ushered in a new era of precision medicine, tailoring therapies to individual patients based on their specific tumor characteristics and genetic makeup.

One of the most promising breakthroughs in gynecological oncology is the advent of targeted therapies. These therapies focus on inhibiting specific molecules or signaling pathways involved in tumor growth, enabling more precise and effective treatment. In ovarian cancer management, PARP inhibitors have emerged as a game-changer, particularly in patients with BRCA mutations [56]. Clinical trials with PARP inhibitors, such as olaparib and niraparib, have demonstrated remarkable efficacy in both the recurrent and maintenance settings, significantly extending progression-free survival and overall survival in patients with BRCA-mutated ovarian cancer [57,58]. Furthermore, studies are ongoing to explore the use of PARP inhibitors in other gynecological cancer subtypes, such as endometrial and cervical cancers, to expand treatment options and improve patient outcomes.

Immunotherapy, another groundbreaking approach in gynecological oncology, has harnessed the body’s immune system to target and eliminate cancer cells. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, have shown remarkable promise in the treatment of certain gynecological cancers [59]. In cervical cancer, for instance, pembrolizumab, an anti-PD-1 inhibitor, has received FDA approval for the treatment of advanced or recurrent disease that has progressed after chemotherapy [60]. Additionally, combining immunotherapies with other treatment modalities, such as chemotherapy and radiation, is an area of active research, as researchers seek to optimize therapeutic responses and increase long-term survival rates.

Another exciting area of progress in gynecological oncology is the emerging role of liquid biopsies in cancer diagnosis and monitoring [61]. Liquid biopsies involve the analysis of circulating tumor DNA (ctDNA) and other biomarkers in a patient’s blood, providing valuable information about the genetic characteristics of the tumor without the need for invasive procedures. In ovarian cancer, liquid biopsies have shown promise in detecting ctDNA mutations associated with chemoresistance, allowing for more informed treatment decisions [62]. Additionally, liquid biopsies have the potential to facilitate early detection and surveillance of endometrial and cervical cancers, reducing the need for invasive procedures and enabling timely intervention [63]. As research in liquid biopsies continues, their integration into routine clinical practice holds the promise of enhancing the diagnostic process, guiding treatment selection, and monitoring treatment response more effectively.

Despite these remarkable innovations, gynecological oncology still faces challenges that warrant further investigation and research. One of the major concerns is the development of drug resistance, limiting the long-term efficacy of targeted therapies and immunotherapies. Additionally, while targeted therapies have shown substantial success in certain patient populations, not all gynecological cancer subtypes exhibit the same level of responsiveness. Identifying novel targets and developing more tailored treatment regimens for specific tumor types is crucial for advancing the field and improving patient outcomes.

Furthermore, the high cost of targeted therapies and immunotherapies poses significant barriers to patient access and affordability. Efforts to increase accessibility to these innovative treatments and address the financial burden on patients are essential to ensuring equitable and optimal cancer care.

Updates in Contraceptive Methods
Contraception plays a vital role in family planning and women’s health. Recent years have witnessed significant advancements in contraceptive methods, offering women a wide range of options to suit their individual needs and preferences. This subtopic aims to analyze the latest developments in contraceptive choices, with a particular focus on long-acting reversible contraceptives (LARCs) and non-hormonal methods, while exploring their potential impact on women’s health.

Long-acting reversible contraceptives (LARCs) have emerged as highly effective and convenient options for women seeking long-term contraception without the need for daily adherence. Among LARCs, intrauterine devices (IUDs) and contraceptive implants have gained popularity due to their efficacy, ease of use, and reversibility [64]. IUDs are available in both hormonal and non-hormonal forms, providing women with a range of choices that suit their specific preferences and health considerations. Hormonal IUDs, such as levonorgestrel-releasing IUDs, not only offer highly effective contraception but also provide various health benefits, including reduced menstrual bleeding and relief of dysmenorrhea [65]. Non-hormonal copper IUDs offer an effective and hormone-free option, ideal for women who cannot or prefer not to use hormonal contraceptives [66]. Contraceptive implants, which release progestin hormones, have also shown high efficacy and satisfaction rates among women [67].

Advancements in LARCs have contributed to their increased utilization worldwide, impacting women’s health positively. LARCs have demonstrated higher contraceptive effectiveness compared to other methods, such as oral contraceptives and condoms, as they significantly reduce the risk of unintended pregnancies [68]. Furthermore, LARCs have shown potential in reducing the incidence of induced abortions and associated maternal morbidity and mortality [69]. The convenience of LARCs, with their long durations of effectiveness, ensures consistent and continuous contraceptive coverage, reducing the likelihood of contraceptive failure and contributing to better family planning outcomes.

In parallel, non-hormonal contraceptive methods have also witnessed notable developments, catering to women seeking hormone-free options or those who experience contraindications or side effects related to hormonal contraceptives. Barrier methods, such as male and female condoms, offer dual protection against unintended pregnancies and sexually transmitted infections [70]. The introduction of innovative female condoms, designed to improve user-friendliness and comfort, has enhanced the appeal of this contraceptive option [71]. Additionally, fertility awareness-based methods, which involve tracking menstrual cycles and identifying fertile days, have gained renewed interest with the development of smartphone apps and wearable devices to aid in accurate cycle tracking [72]. These non-hormonal methods empower women with greater control over their reproductive choices while minimizing potential hormonal side effects.

Furthermore, the potential impact of contraceptive methods on women’s health extends beyond their primary role in family planning. Some hormonal contraceptives have demonstrated benefits beyond contraception, such as reducing the risk of certain gynecological conditions. For instance, combined oral contraceptives have been associated with a reduced risk of endometrial and ovarian cancers [73,74]. Additionally, certain hormonal contraceptives have been utilized to manage menstrual disorders, such as polycystic ovary syndrome (PCOS) and endometriosis, providing relief to affected women [75,76]. However, it is essential to consider individual health profiles and preferences when choosing contraceptive methods, as hormonal contraceptives may not be suitable for all women, and non-hormonal options should be available and accessible [77].

Digital Health and Telemedicine in Gynecology
In recent years, the landscape of healthcare has been transformed by the integration of digital health tools, mobile applications, and telemedicine. Gynecology, as a specialized medical field, has not been exempt from these advancements, with increasing adoption of digital technologies to enhance patient care, improve access, and optimize clinical outcomes. This subtopic aims to examine the role and impact of digital health and telemedicine in gynecological care, exploring how these innovations are revolutionizing patient-provider interactions and improving overall healthcare delivery.

One of the most significant contributions of digital health in gynecology is the development of mobile applications tailored to women’s health needs. Mobile apps offer a range of features, including menstrual cycle tracking, fertility monitoring, contraceptive reminders, and educational resources on reproductive health [78]. These apps empower women to take charge of their health, enabling them to track their menstrual cycles, ovulation, and other important health indicators conveniently. Additionally, mobile apps have facilitated the practice of fertility awareness-based methods, providing women with accurate and personalized information to aid in family planning [79]. The availability of evidence-based information through these apps fosters informed decision-making and empowers women to actively engage in their healthcare.

Moreover, telemedicine has emerged as a game-changer in gynecological care, especially in underserved and remote areas. Telemedicine leverages technology to enable remote consultations between patients and healthcare providers, breaking down geographical barriers and enhancing patient access to specialized care [80]. For women facing geographical constraints or limited access to gynecological services, telemedicine offers a lifeline, connecting them with expert providers regardless of their location. This is particularly significant in the context of reproductive and maternal healthcare, where timely access to care can be critical for ensuring positive outcomes [81]. Telemedicine consultations for prenatal care, family planning counseling, and postoperative follow-ups have demonstrated comparable clinical effectiveness to in-person visits [82,83].

Digital health and telemedicine have also paved the way for remote monitoring of certain gynecological conditions, such as gestational diabetes and high-risk pregnancies. Mobile health devices and wearables can provide real-time data on maternal and fetal health parameters, allowing healthcare providers to identify potential issues early and intervene promptly [84,85]. Furthermore, telemonitoring has shown promise in the management of chronic gynecological conditions, such as polycystic ovary syndrome (PCOS) and endometriosis, enabling personalized care plans and reducing the burden of frequent in-person visits [86,87].

Despite these promising advancements, challenges exist in the widespread adoption of digital health and telemedicine in gynecological care. Privacy and data security concerns, regulatory compliance, and disparities in access to digital technologies are critical factors that require attention [88]. Ensuring patient confidentiality and data protection are paramount in the implementation of digital health solutions. Moreover, equitable access to digital tools and telemedicine services is crucial to avoid exacerbating existing healthcare disparities.

Management of Menopause and Hormonal Therapies
Menopause is a natural biological process marking the end of a woman’s reproductive years, accompanied by a range of hormonal and physiological changes. The management of menopausal symptoms is an essential aspect of women’s health, aiming to improve quality of life and mitigate potential long-term health risks associated with hormonal fluctuations. This subtopic reviews the latest research on managing menopausal symptoms and explores the safety and efficacy of hormonal therapies, with a particular focus on bioidentical hormones.

Hormonal therapies have long been a mainstay in managing menopausal symptoms, including vasomotor symptoms (hot flashes and night sweats), vaginal atrophy, and mood disturbances. Estrogen therapy, either alone (ET) for women without a uterus or in combination with progestin (EPT) for women with a uterus, is the most effective treatment for alleviating menopausal symptoms [89]. Numerous randomized controlled trials and observational studies have demonstrated the efficacy of hormone therapy in reducing hot flashes, improving vaginal health, and enhancing overall well-being [90,91]. Furthermore, hormone therapy has shown positive effects on bone health, reducing the risk of osteoporotic fractures [92].

In recent years, the concept of bioidentical hormones has gained popularity in menopausal management. Bioidentical hormones refer to hormones that have an identical molecular structure to endogenous hormones, such as estradiol and progesterone, synthesized from plant-based sources [93]. Proponents of bioidentical hormones claim that these compounds are more natural and safer than conventional hormone therapy. However, the evidence supporting the superiority or safety of bioidentical hormones over conventional hormone therapy is limited [94]. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have emphasized that compounded bioidentical hormones are not FDA-approved drugs and may lack rigorous safety and efficacy data [95]. More research is needed to establish the safety and long-term outcomes of bioidentical hormone therapy.

In addition to hormonal therapies, non-hormonal treatments have also emerged as viable options for managing menopausal symptoms. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have shown efficacy in reducing hot flashes and improving mood in menopausal women [96]. These medications act on the central nervous system to modulate neurotransmitters, providing an alternative for women who cannot or prefer not to use hormonal therapies [97]. Moreover, certain herbal supplements, such as black cohosh and red clover, have been investigated for their potential in alleviating menopausal symptoms, although evidence remains mixed [98].

Ensuring the safety and efficacy of hormonal therapies is of utmost importance, given the potential risks associated with long-term use. The Women’s Health Initiative (WHI) study, a landmark clinical trial, raised concerns about the safety of hormone therapy, particularly in older women [99]. The study revealed an increased risk of cardiovascular events and breast cancer in women receiving estrogen-progestin therapy, leading to a decline in hormone therapy use in postmenopausal women. Subsequent analyses have shown that the risks associated with hormone therapy are largely influenced by factors such as age at initiation, duration of use, and underlying health conditions [100]. Individualized approaches to prescribing hormone therapy, considering a woman’s age, menopausal stage, and health history, are vital in optimizing the benefits and minimizing potential risks.

Emerging Infectious Diseases in Gynecology
The landscape of infectious diseases is ever-evolving, with emerging pathogens posing unique challenges to public health. In recent years, several infectious agents have been implicated in gynecological health, with growing evidence suggesting potential links between certain viruses and gynecological conditions. This subtopic investigates the impact of emerging infectious diseases on gynecological health, focusing on the association between specific viruses and gynecological conditions.

Human papillomavirus (HPV) stands out as a prominent viral infection significantly impacting gynecological health. HPV is a common sexually transmitted infection, and while most infections are transient and clear spontaneously, persistent infections with high-risk HPV genotypes can lead to the development of cervical, vulvar, vaginal, anal, and oropharyngeal cancers [101]. Cervical cancer is the most well-established association with high-risk HPV infection, with HPV types 16 and 18 being the most prevalent causative agents [102]. Regular cervical screening programs, including Pap smears and HPV testing, have been crucial in early detection and the prevention of cervical cancer in high-income countries. However, cervical cancer remains a significant health burden, particularly in low- and middle-income countries where access to screening and HPV vaccination is limited [103].

Additionally, emerging viruses have been linked to gynecological conditions beyond cervical cancer. For instance, Zika virus, a mosquito-borne pathogen, emerged as a global health concern due to its association with congenital Zika syndrome and other reproductive complications. Zika virus infection during pregnancy has been linked to severe fetal brain abnormalities and microcephaly [104]. The virus has also been detected in vaginal secretions and has raised concerns about potential sexual transmission [105]. While the outbreak of Zika virus has waned, continued surveillance and monitoring of potential long-term effects on women’s reproductive health remain essential.

Furthermore, the association between viral infections and gynecological conditions extends to the realm of reproductive health and infertility. Emerging evidence suggests a potential link between viral infections and tubal factor infertility [106]. Chronic infections with viruses such as Chlamydia trachomatis and Neisseria gonorrhoeae have been associated with salpingitis (inflammation of the fallopian tubes), leading to tubal damage and subsequent infertility [107]. Similarly, viral infections, such as human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV), have been implicated in impairing sperm function and male infertility [108].

As emerging infectious diseases continue to pose challenges, vaccination has emerged as a crucial preventive strategy. HPV vaccines have demonstrated remarkable efficacy in preventing HPV infections and related gynecological conditions [109]. These vaccines target high-risk HPV genotypes and have shown promise in reducing the incidence of cervical precancerous lesions and genital warts [110]. Expanding vaccine coverage and access to HPV vaccination remains a priority to combat cervical cancer and other HPV-related gynecological conditions globally.

Despite the advances in our understanding of the association between viruses and gynecological health, further research is needed to elucidate the mechanisms of viral pathogenesis and its implications on reproductive health. Continued surveillance and international collaboration are essential to monitor emerging infectious diseases and their impact on gynecological health. Moreover, public health efforts should focus on promoting comprehensive sexual education, early detection through screening programs, and timely vaccination to mitigate the burden of infectious diseases in gynecology.

Psychological and Social Aspects of Women’s Health
Women’s health encompasses not only the physical aspects of well-being but also the psychological and social dimensions that significantly influence overall health outcomes. The field of gynecology recognizes the integral role of mental health in women’s reproductive health, with emerging evidence highlighting the impact of stress, anxiety, and depression on various gynecological conditions. This subtopic explores the interplay between mental health and gynecological health, emphasizing the importance of adopting a holistic approach to care that addresses both physical and emotional well-being.

Stress, anxiety, and depression are common experiences among women and can have significant implications for reproductive health. Stress, in particular, can disrupt the delicate hormonal balance, leading to irregular menstrual cycles and suboptimal fertility [111]. Chronic stress may contribute to alterations in the hypothalamic-pituitary-ovarian axis, affecting ovulation and menstrual regularity [112]. Furthermore, stress has been linked to adverse pregnancy outcomes, including preterm birth and low birth weight [113]. Identifying stressors and implementing stress management techniques, such as mindfulness-based interventions and cognitive-behavioral therapy, can be valuable in supporting women’s reproductive health [114].

Anxiety and depression are also prevalent mental health concerns affecting women, and both conditions can impact gynecological health in unique ways. Anxiety can manifest as somatic symptoms, leading to increased healthcare utilization and diagnostic challenges [115]. Additionally, anxiety disorders have been associated with an increased risk of premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome characterized by intense mood swings and physical symptoms [116]. Depression, on the other hand, has been linked to disrupted menstrual cycles and alterations in hormonal profiles [117]. Moreover, depression during pregnancy has been associated with adverse maternal and infant outcomes, including preterm birth and developmental delays [118]. Integrating mental health screening and early intervention within gynecological care can help identify women at risk and offer appropriate support and treatment.

A holistic approach to women’s health in gynecology involves addressing the broader social determinants that impact health outcomes. Socioeconomic factors, access to healthcare, and cultural beliefs can all influence women’s health experiences [119]. For instance, disparities in access to reproductive healthcare can lead to delayed diagnosis and suboptimal management of gynecological conditions [120]. Furthermore, cultural stigmatization surrounding certain gynecological issues, such as infertility or menopause, may impede women from seeking appropriate care [121]. Healthcare providers should adopt a culturally sensitive and patient-centered approach, recognizing the diverse needs and experiences of women in their care.

Moreover, addressing mental health concerns should be an integral part of gynecological care, fostering collaboration between gynecologists and mental health professionals. Integrating mental health screening and assessment tools into routine gynecological visits can facilitate early identification of mental health concerns and facilitate timely referrals for specialized care [122]. Collaborative care models, where gynecologists and mental health providers work together to manage complex cases, have shown promise in improving patient outcomes and satisfaction [123].

Patient Perspectives and Shared Decision-Making
Patient-centered care has become a cornerstone of modern healthcare, recognizing the importance of involving patients in their own care and decision-making processes. In the field of gynecology, where treatment choices can have significant and far-reaching effects on women’s lives, patient perspectives and shared decision-making play a crucial role in achieving optimal outcomes and patient satisfaction. This subtopic highlights the significance of patient-centered care in gynecology and explores the role of shared decision-making and patient preferences in treatment choices.

Patient-centered care emphasizes the importance of understanding each patient’s unique needs, values, and preferences and incorporating these factors into the decision-making process [124]. In gynecology, this approach is particularly relevant, as many treatment options are available for various gynecological conditions, each with its own benefits and risks. A patient’s age, reproductive goals, cultural background, and personal preferences can all influence the best course of action for their individual case [125]. Engaging patients in shared decision-making fosters a collaborative relationship between healthcare providers and patients, ensuring that the chosen treatment aligns with the patient’s values and goals.

Shared decision-making involves a transparent and interactive process between healthcare providers and patients, where information about different treatment options, including their potential benefits and risks, is presented in an accessible manner [126]. Patients are encouraged to ask questions and express their concerns, and healthcare providers work with patients to explore all viable options and arrive at a mutually agreed-upon treatment plan. In gynecology, shared decision-making is particularly pertinent in cases where treatment choices involve complex trade-offs, such as in the management of uterine fibroids, endometriosis, or early-stage gynecological cancers [127]. Research has shown that engaging in shared decision-making leads to greater patient satisfaction, increased adherence to treatment plans, and improved health outcomes [128].

Patient perspectives in gynecology encompass a wide range of concerns, including fertility desires, sexual health, and quality of life considerations. For instance, in cases of gynecological cancers, women may place significant importance on preserving fertility and maintaining sexual function after treatment [129]. In such situations, fertility-preserving surgeries or assisted reproductive technologies may be viable options, and shared decision-making becomes crucial in weighing the potential benefits and risks of different approaches [130]. Additionally, for women experiencing symptoms related to menopause, such as hot flashes, mood disturbances, and vaginal dryness, patient preferences may influence the choice between hormonal and non-hormonal therapies [131].

Implementing patient-centered care and shared decision-making in gynecology requires effective communication and a willingness to engage with patients in a collaborative manner. Healthcare providers should strive to create a supportive and empathetic environment where patients feel comfortable sharing their concerns and preferences [132]. Employing decision aids, such as visual aids and written materials, can facilitate the understanding of treatment options and enhance patient involvement in the decision-making process [133]. Moreover, fostering cultural competence and awareness of diverse patient backgrounds is essential in addressing the unique needs and perspectives of women from different communities [134].

Coclusion
The field of gynecology has witnessed remarkable advancements, shaping the landscape of women’s health and revolutionizing the approach to gynecological care. This comprehensive review article explored diverse subtopics, ranging from minimally invasive gynecological procedures and precision medicine to breakthroughs in reproductive medicine, gynecological oncology, and emerging infectious diseases. The discussion also encompassed updates in contraceptive methods, digital health integration, management of menopause, psychological aspects of women’s health, patient-centered care, and shared decision-making. Each subtopic presented evidence-based insights and highlighted the potential impact on patient outcomes and well-being.

The evidence discussed in this review demonstrates the power of innovation and research in improving gynecological care. Minimally invasive procedures have emerged as the gold standard for various gynecological conditions, offering less invasive alternatives and promoting faster recovery. Precision medicine and personalized approaches hold promise in tailoring treatments to individual needs and optimizing outcomes. In the realm of reproductive medicine, advancements in assisted reproductive technologies have brought hope to couples facing infertility, while innovations in gynecological oncology have expanded treatment options and improved survival rates for women with gynecological cancers. Furthermore, the integration of digital health tools and telemedicine has facilitated better access to care and empowered women to take an active role in their health management. Psychological and social aspects of women’s health have gained deserved attention, emphasizing the significance of mental health in gynecological care and advocating for patient-centered approaches that consider the unique perspectives and values of each woman.

In conclusion, this literature review underscores the dynamic nature of gynecology, wherein research and innovation continue to shape the future of women’s health. By staying abreast of emerging trends and adopting evidence-based practices, healthcare providers can deliver personalized and compassionate care to women at every stage of life. As we move forward, fostering interdisciplinary collaborations, advocating for equitable access to care, and integrating patient perspectives into decision-making processes will further enhance gynecological care and contribute to the well-being and empowerment of women worldwide. By embracing progress and prioritizing the holistic needs of patients, gynecology can continue to flourish as a vital specialty, dedicated to improving the health and quality of life for women across the globe.

Declarations
Ethics Approval and Consent to Participate: “NOT APPLICABLE”
Consent for Publication: “NOT APPLICABLE”
Availability of Data and Material: “Data sharing not applicable to this article as no data-sets were generated or analyzed during the current study”
Competing Interests: “The authors declare that they have no competing interests.”
Funding: “NOT APPLICABLE”
Acknowledgements: “NOT APPLICABLE”

References

1. Clark TJ, Middleton LJ, Cooper NA. A randomised controlled trial of laparoscopic uterosacral nerve ablation for women with chronic pelvic pain. BMJ Open. 2015. 5: e006408.
2. Advincula AP, Song A, Burke W, Reynolds RK. Preliminary experience with robot-assisted laparoscopic myomectomy. J Am Assoc Gynecol Laparosc. 2004. 11: 511-518.
3. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015. 372: 793-795.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011. 144: 646-674.
5. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400,135 treatment cycles. PLoS Med. 2011. 8: e1000384.
6. Gleicher N, Barad DH. A review of early prenatal diagnosis in preimplantation genetic diagnosis cycles by assessment of fetal losses after amniocentesis or chorionic villus sampling in patients with infertility and preimplantation genetic screening cycles. Fertil Steril. 2007. 88: 82-86.
7. Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol. 2019. 37: 5506.
8. Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016. 6: 1382-1399.
9. Bahamondes L, Makuch MY, Monteiro I. The effect upon bleeding patterns of the levonorgestrel-releasing intrauterine system when used for contraception during lactation. Contraception. 2002. 65: 87-91.
10. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception. 2009. 80: 327-336.
11. Lee JK, Groessl EJ, Ganiats TG. Implementation of gynecologic electronic health records: defects, workarounds, and solutions. Obstet Gynecol. 2011. 118: 849-857.
12. Aranda-Jan CB, Mohutsiwa-Dibe N, Loukanova S. Systematic review on what works, what does not work and why of implementation of mobile health (mHealth) projects in Africa. BMC Public Health. 2014. 14: 188.
13. Sturdee DW, Pines A, International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011. 14: 302-320.
14. Rezai S, Akbari S, Abdollahi M. A review of the systemic adverse effects of topical dorzolamide. Curr Clin Pharmacol. 2012. 7: 185-189.
15. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med. 2000. 342: 1500-1507.
16. Beigi RH. Pandemic influenza and pregnancy: a call for preparedness planning. Obstet Gynecol. 2012. 120: 995-998.
17. Young S, Lamping D, Lontos S. Efficacy and safety of estrogen treatment in depressive disorders: systematic review and meta-analysis. Lancet Psychiatry. 2019. 6: 29-39.
18. Young S, Pfaff D. Hormones and Memory. In: Pfaff DW, Joëls M, eds. Hormones, Brain, and Behavior. 3rd edition. Academic Press. 2017. 2017: 445-474.
19. Barr PJ, Thompson R, Walsh T, Grande SW, Ozanne EM, et al. The psychometric properties of CollaboRATE: a fast and frugal patient-reported measure of the shared decision-making process. J Med Internet Res. 2014. 16: e2.
20. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, et al. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. BMJ. 2014. 349: 6501.
21. Aarts JW, Nieboer TE, Johnson N, Tavender E, Garry R, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2015. 8: CD003677.
22. Sarlos D, Kots L, Stevanovic N, Schaer G. Robotic compared with conventional laparoscopic hysterectomy: a randomized controlled trial. Obstet Gynecol. 2012. 120: 604-611.
23. Payne TN, Dauterive FR. A comparison of total laparoscopic hysterectomy to robotically assisted hysterectomy: surgical outcomes in a community practice. J Minim Invasive Gynecol. 2008. 15: 286-291.
24. Serur E, Gargiulo T. Robotic gynecologic surgery. Fertil Steril. 2011. 95: 2125.e15-2125.e19.
25. Holloway RW, Patel SD, Ahmad S, Robichaux AG, Goravanchi F, et al. Robotically assisted gynecologic surgery in the obese patient. Am J Obstet Gynecol. 2009. 200: 613.e1-613.e4.
26. Advincula AP, Xu X, Goudeau S, Ransom SB. Robot-assisted laparoscopic myomectomy versus abdominal myomectomy: a comparison of short-term surgical outcomes and immediate costs. J Minim Invasive Gynecol. 2007. 14: 698-705.
27. Park JY, Seong SJ, Kim TJ. Robotic versus laparoscopic radical hysterectomy for cervical cancer: a comparison of perioperative outcomes. J Gynecol Oncol. 2013. 24: 55-61.
28. Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol. 2008. 199: 360.e1-360.e9.
29. Kim M, Lee MY, Lee D, Kim S, Park SY. Comparison of surgical outcomes between laparoscopic and robotic surgery in women with early-stage endometrial cancer: a systematic review and meta-analysis. Cancers (Basel). 2021. 13: 1115.
30. Ramalli EL, Pinton AQ, Serafini PC, Castro EB, Rivoire HC. Robot-assisted laparoscopic treatment of early-stage cervical cancer: analysis of 20 cases. Int J Med Robot. 2017. 13: e1803.
31. Cusimano MC, Simpson AN, Dossa F. Oncologic outcomes and complications after minimally invasive radical hysterectomy for early-stage cervical cancer: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2019. 26: 224-237.
32. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008. 9: 297-303.
33. Kim HS, Sardi A, Lapolla JP, Kim N, Obermair A. A systematic review and meta-analysis of robotic surgery compared with conventional laparoscopic and open surgery in the treatment of early-stage endometrial cancer. Int J Gynecol Cancer. 2021. 31: 51-61.
34. Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV 3rd, Micha JP, et al. The learning curve of robotic surgery for endometrial cancer: a single-institution experience. J Robot Surg. 2010. 4: 243-246.
35. Lim PC, Kang E, Park do J. Learning curve and surgical outcome for robotic-assisted hysterectomy with lymphadenectomy: case-matched controlled comparison with laparoscopy and laparotomy for treatment of endometrial cancer. J Minim Invasive Gynecol. 2010. 17: 739-748.
36. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007. 96: 11-15.
37. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017. 147: 267-275.
38. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013. 497: 67-73.
39. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010. 116: 15-20.
40. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017. 357: 409-413.
41. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983. 309: 883-887.
42. Moore RG, Miller MC, Eklund EE, et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012. 206: 349.e1-349.e7.
43. Fiorentino F, Biricik A, Bono S. Development, validation and clinical application of a protocol for preimplantation genetic diagnosis of numerical chromosomal abnormalities. Hum Reprod. 2011. 26: 543-550.
44. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014. 20: 124-140.
45. Giri VN, Hegarty SE, Hyatt C. Germline genetic testing for inherited cancer risk in the era of next-generation sequencing. JAMA Oncol. 2016. 2: 717-725.
46. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet. 1978. 2: 366.
47. Bhattacharya S, Maheshwari A, Mollison J. Factors associated with failed treatment: an analysis of 121,744 women embarking on their first IVF cycles. PLoS One. 2013. 8: e82249.
48. Palermo GD, Neri QV, Takeuchi T, Squires J, Moy F, et al. Genetic and epigenetic characteristics of ICSI children. Reprod Biomed Online. 2008. 17: 820-833.
49. Meseguer M, Herrero J, Tejera A, Hilligsøe KM, Ramsing NB, et al. The use of morphokinetics as a predictor of embryo implantation. Hum Reprod. 2011. 26: 2658-2671.
50. Fiorentino F, Biricik A, Bono S. Development, validation and clinical application of a protocol for preimplantation genetic diagnosis of numerical chromosomal abnormalities. Hum Reprod. 2011. 26: 543-550.
51. Thornhill AR, deDie-Smulders CE, Geraedts JP, Harper JC, Harton GL, et al. ESHRE PGD Consortium ‘Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)’. Hum Reprod. 2005. 20: 35-48.
52. Cobo A, García-Velasco JA, Domingo J, Remohí J, Pellicer A. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil Steril. 2013. 99: 1485-1495.
53. Donnez J, Dolmans MM, Diaz C, Pellicer A. Ovarian cortex transplantation: time to move on from experimental studies to open clinical application. Fertil Steril. 2015. 104: 1097-1098.
54. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015. 13: 37.
55. Poels J, Abou-Ghannam G, Decanter C, Pigny P, Lefebvre-Maunoury C, et al. Fertility preservation in boys: recent developments and new insights. Hum Reprod. 2017. 32: 1934-1941.
56. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014. 15: 852-861.
57. Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017. 18: 1274-1284.
58. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016. 375: 2154-2164.
59. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (GOG-0240). Lancet. 2017. 390: 1654-1663.
60. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015. 348: 56-61.
61. FDA grants accelerated approval to pembrolizumab for advanced cervical cancer with disease progression during or after chemotherapy. U.S. Food and Drug Administration (FDA). 2018. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-advanced-cervical-cancer-disease-progression-during-or.
62. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014. 32: 579-586.
63. Heidary M, Auer M, Ulz P, Heitzer E, Petru E, et al. The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. 2014. 16: 421.
64. Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJ, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019. 154: 441-448.
65. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012. 366: 1998-2007.
66. Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, et al. Effects of progestin-only long-acting reversible contraceptives on weight and body mass index in obese women. Obstet Gynecol. 2013. 121: 1098-1106.
67. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception. 2007. 75: S16-S30.
68. Lopez LM, Bernholc A, Hubacher D, Stuart G, Van Vliet HA. Immediate start of hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014. 10: CD006260.
69. Trussell J. Contraceptive failure in the United States. Contraception. 2011. 83: 397-404.
70. Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A. Contraception and health. Lancet. 2012. 380: 149-156.
71. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, et al. Cost effectiveness of contraceptives in the United States. Contraception. 2009. 79: 5-14.
72. World Health Organization (WHO). Family planning/Contraception. Available at: https://www.who.int/news-room/q-a-detail/family-planning-contraception.
73. Gemzell-Danielsson K, Apter D, Hauck B. The effect of age on the efficacy of a progesterone-releasing vaginal ring as a contraceptive method. Contraception. 2013. 88: 410-416.
74. IARC Working Group on Hormonal Contraception and Postmenopausal Hormonal Therapy. Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. IARC Monogr Eval Carcinog Risks Hum. 2007. 91: 1-528.
75. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017. 377: 2228-2239.
76. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2011. 11: CD006133.
77. Słopień R, Męczekalski B, Wizyta-Paradysz A, Nahorski W. Role of hormonal contraception in the management of polycystic ovary syndrome. Gynecol Endocrinol. 2014. 30: 431-434.
78. Aungst TD. Medical applications for pharmacists using mobile devices. Ann Pharmacother. 2013. 47: 1088-1095.
79. Freis A, Freundl-Schütt T, Wallwiener LM, Wallwiener CW, Wallwiener D. Bioinformatics support for the fertility awareness-based methods in avoiding pregnancy. Reprod Biomed Online. 2017. 35: 308-316.
80. Ong MS, Magrabi F, Post J, Morris S, Westbrook JI. Use of clinical decision support to improve primary care identifies targets for improvement in the outpatient referral process. J Am Med Inform Assoc. 2016. 23: 609-615.
81. Yellowlees PM, Odor A, Parish MB, Iosif AM, Haught K, et al. A feasibility study of the use of asynchronous telepsychiatry for psychiatric consultations. Psychiatr Serv. 2010. 61: 838-840.
82. Silverstein W, Lass E, Bornstein T. A randomized clinical trial of a telemedicine intervention for child disruptive behavior disorders: III. Maintenance and generalization of effects. J Abnorm Child Psychol. 2018. 46: 1285-1298.
83. Rabee A, Kellie S. Acceptability and usability of telemedicine for women’s health consultations: A systematic review. JMIR Mhealth Uhealth. 2019. 7: e13165.
84. Davenport MH, Marchand AA, Mottola MF, Poitras VJ, Gray CE, et al. Exercise for the prevention and treatment of maternal-fetal disease: A review of the literature. Appl Physiol Nutr Metab. 2018. 43: 1159-1174.
85. Inan OT, Tenaerts P, Prindiville S. The changing landscape of clinical trials in the era of big data: mobile health, electronic data capture, and electronic health records. EPMA J. 2018. 9: 279-290.
86. Palmieri C, Iadarola R, Magri F. Telemedicine in endometriosis: An additional tool in patients’ management. J Minim Invasive Gynecol. 2018. 25: 846-847.
87. Naher L, Biondi-Zoccai G, Saha S, Palma G, Trimarchi F. A meta-analysis of telemedicine interventions for chronic heart failure patients. Can J Cardiol. 2013. 29: 1466-1474.
88. Wac K, Wac K, Prakoonwit S, Widya I, Jara AJ. Mobile healthcare and resource-constrained communities: a case study from Thailand. J Med Syst. 2012. 36: 1437-1451.
89. Santen RJ, Allred DC, Ardoin SP. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010. 95: S1-S66.
90. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002. 288: 321-333.
91. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013. 310: 1353-1368.
92. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women’s Health Initiative randomized trial. JAMA. 2003. 290: 1729-1738.
93. Cirigliano M, Gava G, Simoncini T. Bioidentical hormone therapy in menopause: Relevance in dermatology. G Ital Dermatol Venereol. 2019. 154: 569-577.
94. Huang A, Ketheeswaranathan P, McCaffrey J, Schembri M. The safety and efficacy of bioidentical hormone replacement therapy in menopausal women: A systematic review and meta-analysis. Fertil Steril. 2019. 112: 483-492.e17.
95. US Food and Drug Administration (FDA). Bio-identicals: Sorting myths from facts. 2019. Available at: https://www.fda.gov/womens-health/bio-identicals-sorting-myths-facts.
96. Pinkerton JV. Hormone replacement therapy and selective serotonin reuptake inhibitor antidepressants: Are they safe together? Menopause. 2019. 26: 1031-1032.
97. Joffe H, Petrillo LF, Koukopoulos A, Viguera AC, Hirschberg A, et al. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab. 2011. 96: 1044-1054.
98. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause. 2003. 10: 465-476.
99. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007. 297: 1465-1477.
100. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women’s Health Initiative randomized trials. JAMA. 2017. 318: 927-938.
101. Schiffman M, Doorbar J, Wentzensen N, De Sanjosé S, Fakhry C, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016. 2: 16086.
102. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999. 189: 12-19.
103. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis. Lancet Glob Health. 2016. 4: 453-463.
104. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects - reviewing the evidence for causality. N Engl J Med. 2016. 374: 1981-1987.
105. Musso D, Ko AI, Baud D. Zika virus infection - after the pandemic. N Engl J Med. 2019. 381: 1444-1457.
106. Egger A, Jakob NJ, Stertz S. Viral evasion of STING-mediated innate immune responses. Front Immunol. 2019. 10: 2147.
107. Taylor BD, Haggerty CL. Management of Chlamydia trachomatis genital tract infection: Screening and treatment challenges. Infect Drug Resist. 2011. 4: 19-29.
108. Chiricozzi A, Gubinelli E, Dini V, Romanelli M. Generalized viral infections and human herpesvirus 6 in two couples with fertility disorders. Arch Dermatol. 2006. 142: 1046-1050.
109. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012. 13: 89-99.
110. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007. 356: 1928-1943.
111. Wissart J, Parshad O, Kulkarni S. Prevalence of premenstrual dysphoric disorder in female patients with common mental disorders. J Affect Disord. 2004. 79: 257-261.
112. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009. 5: 374-381.
113. Rondó PH, Ferreira RF, Nogueira F, Ribeiro MC, Lobert H, et al. Maternal psychological stress and distress as predictors of low birth weight, prematurity and intrauterine growth retardation. Eur J Clin Nutr. 2003. 57: 266-272.
114. Raja SN, Hasenbring MI. Stress and pain: from dawn to dusk. Exp Brain Res. 2008. 184: 1-3.
115. Rydmark I, Wahlberg K, Ghatan PH, Modell S, Nygren Å, et al. Neuroendocrine, cognitive and structural imaging characteristics of women on longterm sickleave with job stress-induced depression. Biol Psychiatry. 2006. 60: 867-873.
116. Backström T. Premenstrual dysphoric disorder: A state-of-the-art review. CNS Drugs. 2014. 28: 389-404.
117. Joffe H, Petrillo LF, Koukopoulos A, Viguera AC, Hirschberg A, et al. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab. 2011. 96: 1044-1054.
118. Field T, Diego M, Hernandez-Reif M, Schanberg S, Kuhn C. Depressed pregnant black women have a greater incidence of prematurity and low birthweight outcomes. Infant Behav Dev. 2009. 32: 10-16.
119. Krieger N. Women and social class: A methodological study comparing individual, household, and census measures as predictors of black/white differences in reproductive history. J Epidemiol Community Health. 1991. 45: 35-42.
120. Adashi EY, Cohen J, Hamberger L, Jones HW. Public-funded elective infertility care in the United States. Obstet Gynecol. 2016. 128: 1201-1205.
121. Emamhadi M, Salehiniya H. Trends in global breast cancer incidence associated with obesity: an ecological study. Asian Pac J Cancer Prev. 2019. 20: 2349-2354.
122. Green LA, Fryer Jr GE, Yawn BP, Lanier D, Dovey SM. The ecology of medical care revisited. N Engl J Med. 2001. 344: 2021-2025.
123. Druss BG, von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry. 2006. 28: 145-153.
124. Epstein RM, Street RL Jr. Shared mind: Communication, decision making, and autonomy in serious illness. Ann Fam Med. 2011. 9: 454-461.
125. Wilkes MS, Day FC, Srinivasan M, Griffin E, Tancredi DJ, et al. Pairing physician education with patient activation to improve shared decisions in prostate cancer screening: A cluster randomized controlled trial. Ann Fam Med. 2013. 11: 324-334.
126. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, et al. Shared decision making: A model for clinical practice. J Gen Intern Med. 2012. 27: 1361-1367.
127. Whistance RN, Conroy T, Chie W, Costantini A, Sezer O, et al. Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. Eur J Cancer. 2009. 45: 3017-3026.
128. Joseph-Williams N, Elwyn G, Edwards A. Knowledge is not power for patients: A systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. Patient Educ Couns. 2014. 94: 291-309.
129. Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, et al. A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol. 2010. 119: 358-365.
130. Park JY, Park SY, Kim DY, Kim YM, Kim YT, et al. Fertility-sparing laparoscopic radical trachelectomy for young women with early stage cervical cancer. BJOG. 2017. 124: 476-483.
131. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014. 17: 3-9.
132. Henselmans I, van Laarhoven HW, van der Vloodt J, Tokat M, Engelhardt EG, et al. Shared decision making about palliative chemotherapy: A qualitative observation of talk about patients’ preferences. Palliat Med. 2015. 29: 261-269.
133. Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017. 4: CD001431.
134. Akl EA, Oxman AD, Herrin J, Vist GE, Terrenato I, et al. Using alternative statistical formats for presenting risks and risk reductions. Cochrane Database Syst Rev. 2011. 3: CD006776.